Press release
Huntington's Disease Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Novartis, Sage Therapeutics, Annexon, Neurocrine Biosciences, Prilenia Therapeutics
"Huntington's Disease Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Huntington's Disease Market.
The Huntington's Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Huntington's Disease Pipeline Report: https://www.delveinsight.com/sample-request/huntingtons-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Huntington's Disease treatment therapies with a considerable amount of success over the years.
• Huntington's Disease companies working in the treatment market are Sangamo Therapeutics, Spark therapeutics, Chong Kun Dang Pharmaceutical, Neuvivo, UniQure Biopharma, Wave Life Sciences, Novartis, Sage Therapeutics, Annexon, Neurocrine Biosciences, Prilenia Therapeutics, and others, are developing therapies for the Huntington's Disease treatment
• Emerging Huntington's Disease therapies in the different phases of clinical trials are- TAK-686, Huntington's Disease therapy, CKD-504, NP 001, rAAV5-miHTT, WVE003, Branaplam, SAGE-718, ANX005, Valbenazine, Pridopidine, and others are expected to have a significant impact on the Huntington's Disease market in the coming years.
• In August 2022, In order to undertake a Phase I/II trial for its innovative Huntington's Disease (HD) gene treatment, BV-101, through its subsidiary BrainVectis in France, Asklepios BioPharmaceutical, a fully owned and independently run subsidiary of Bayer AG, got approval. The National Agency for Safety of Medicines and Health Products (ANSM), the nation's regulatory drug agency, has granted the corporation permission to start seeking volunteers after the relevant Ethics Committee approved the trial protocol.
• In March 2022, The PIVOT-HD Phase II clinical trial investigating PTC518 in patients with Huntington's disease (HD) has begun, according to PTC Therapeutics. An international trial called PIVOT-HD is beginning in the US. PTC518 is a small chemical splicing modifier that may be taken orally and was created specifically to reduce huntingtin mRNA and protein. The underlying cause of HD is not currently being treated
• In January 2022, A new Phase II trial to assess tominersen in Huntington's disease (HD) has been planned, according to an announcement by Ionis Pharmaceuticals and its partner Roche. Tominersen may benefit younger adult patients with reduced disease load, according to exploratory posthoc analysis conducted after treatment in the Phase III GENERATION HD1 study was stopped. It is necessary to confirm these findings in a randomised, placebo-controlled trial
• On November 17, 2021, Pridiopidine was given the Fast Track designation by the US Food and Drug Administration for development as a potential treatment for Huntington's disease (HD). In the US and the EU, Prilenia has been granted Orphan Drug Designation for the use of pridopidine in the treatment of HD.
Huntington's Disease Overview
Huntington's disease is a genetically transmitted, neurodegenerative ailment that gradually impairs cognitive function and memory (dementia) as well as the development of uncontrollable motions of the hands, feet, face, and body.
Get a Free Sample PDF Report to know more about Huntington's Disease Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/huntingtons-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Huntington's Disease Drugs Under Different Phases of Clinical Development Include:
• TAK-686: Sangamo Therapeutics
• Huntington's Disease therapy: Spark therapeutics
• CKD-504: Chong Kun Dang Pharmaceutical
• NP 001: Neuvivo
• rAAV5-miHTT: UniQure Biopharma
• WVE003 : Wave Life Sciences
• Branaplam: Novartis
• SAGE-718: Sage Therapeutics
• ANX005: Annexon
• Valbenazine: Neurocrine Biosciences
• Pridopidine: Prilenia Therapeutics
• Tominersen: Ionis Pharmaceuticals
Huntington's Disease Route of Administration
Huntington's Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Huntington's Disease Molecule Type
Huntington's Disease Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Huntington's Disease Pipeline Therapeutics Assessment
• Huntington's Disease Assessment by Product Type
• Huntington's Disease By Stage and Product Type
• Huntington's Disease Assessment by Route of Administration
• Huntington's Disease By Stage and Route of Administration
• Huntington's Disease Assessment by Molecule Type
• Huntington's Disease by Stage and Molecule Type
DelveInsight's Huntington's Disease Report covers around 5+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Huntington's Disease product details are provided in the report. Download the Huntington's Disease pipeline report to learn more about the emerging Huntington's Disease therapies at:
https://www.delveinsight.com/sample-request/huntingtons-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Huntington's Disease Therapeutics Market include:
Key companies developing therapies for Huntington's Disease are - Prilenia Therapeutics, Ionis Pharmaceuticals, Annexon, Vaccinex, Neurocrine Biosciences, SAGE Therapeutics, PTC Therapeutics, WaVe life Sciences, Novartis, Neurimmune Therapeutics, SOLA Biosciences, UniQure Biopharma, Roche, Annexon, Inc., Azevan Pharmaceuticals, SOM Innovation Biotech SA, Asklepios BioPharmaceutical, Luye Pharma Group Ltd., BrainStorm Cell Therapeutics, Voyager Therapeutics, Passage Bio, Locana Bio, Ceptur Therapeutics, Enzerna Biosciences, AFFiRiS AG, Arvinas, Atalanta Therapeutics, Anima Biotech, and others.
Huntington's Disease Pipeline Analysis:
The Huntington's Disease pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Huntington's Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Huntington's Disease Treatment.
• Huntington's Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Huntington's Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Huntington's Disease market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Huntington's Disease drugs and therapies- https://www.delveinsight.com/sample-request/huntingtons-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Huntington's Disease Pipeline Market Drivers
• Introduction of disease-modifying drugs, further understanding in pathogenesis are some of the important factors that are fueling the Huntington's Disease Market.
Huntington's Disease Pipeline Market Barriers
• However, lesser approved therapies, stringent regulations and other factors are creating obstacles in the Huntington's Disease Market growth.
Scope of Huntington's Disease Pipeline Drug Insight
• Coverage: Global
• Key Huntington's Disease Companies: Sangamo Therapeutics, Spark therapeutics, Chong Kun Dang Pharmaceutical, Neuvivo, UniQure Biopharma, Wave Life Sciences, Novartis, Sage Therapeutics, Annexon, Neurocrine Biosciences, Prilenia Therapeutics, and others
• Key Huntington's Disease Therapies: TAK-686, Huntington's Disease therapy, CKD-504, NP 001, rAAV5-miHTT, WVE003, Branaplam, SAGE-718, ANX005, Valbenazine, Pridopidine, and others
• Huntington's Disease Therapeutic Assessment: Huntington's Disease current marketed and Huntington's Disease emerging therapies
• Huntington's Disease Market Dynamics: Huntington's Disease market drivers and Huntington's Disease market barriers
Request for Sample PDF Report for Huntington's Disease Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/huntingtons-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Huntington's Disease Report Introduction
2. Huntington's Disease Executive Summary
3. Huntington's Disease Overview
4. Huntington's Disease- Analytical Perspective In-depth Commercial Assessment
5. Huntington's Disease Pipeline Therapeutics
6. Huntington's Disease Late Stage Products (Phase II/III)
7. Huntington's Disease Mid Stage Products (Phase II)
8. Huntington's Disease Early Stage Products (Phase I)
9. Huntington's Disease Preclinical Stage Products
10. Huntington's Disease Therapeutics Assessment
11. Huntington's Disease Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Huntington's Disease Key Companies
14. Huntington's Disease Key Products
15. Huntington's Disease Unmet Needs
16 . Huntington's Disease Market Drivers and Barriers
17. Huntington's Disease Future Perspectives and Conclusion
18. Huntington's Disease Analyst Views
19. Appendix
20. About DelveInsight
Related Reports:
Huntington's Disease Market https://www.delveinsight.com/report-store/huntingtons-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Huntington's Disease-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Huntington's Disease Epidemiology https://www.delveinsight.com/report-store/huntingtons-disease-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Huntington's Disease Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports:
Monkeypox Market https://www.delveinsight.com/report-store/monkeypox-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Monkeypox Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Pars Planitis Market
https://www.delveinsight.com/report-store/pars-plantis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Pars Plantis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Pars Plantis, historical and forecasted epidemiology as well as the Pars Plantis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products
Typhoid Market https://www.delveinsight.com/report-store/typhoid-fever-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Zika Virus Market https://www.delveinsight.com/report-store/zika-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Opioid Use Disorder Market https://www.delveinsight.com/report-store/opioid-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Opioid Use Disorder (OUD) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Huntington's Disease Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Novartis, Sage Therapeutics, Annexon, Neurocrine Biosciences, Prilenia Therapeutics here
News-ID: 3134209 • Views: …
More Releases from DelveInsight Business Research
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals.
Objective of the Case Study
The…
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics.
According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than…
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies.
Biopsy devices play a crucial role in disease diagnosis by…
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide.
DelveInsight's General Surgery Devices Market Report 2032 provides…
More Releases for Huntington
AC Company in Huntington Upgrades Emergency Response Capabilities
As temperatures climb and air conditioners are pushed to their limits, many systems begin to fail under strain.
Residents searching for a dependable ac company near me [https://summersphc.com/huntington/] in Huntington, IN, may notice faster response times and improved service delivery this summer. That's because Summers Plumbing Heating & Cooling has invested in enhancing its emergency HVAC response systems to meet the rising demand for rapid cooling solutions during heatwaves and mechanical…
Reliable AC Installation Now Available for Huntington Homeowners
Whether you're upgrading from an outdated unit or installing a brand-new system, having a team that understands your specific needs is key.
When temperatures rise and older systems falter, many homeowners start looking for AC installation near me [https://www.google.com/search?ac+installation+near+me&kgmid=/g/11tp8xn78c] to find the right solution for reliable cooling. In Huntington, a trusted name now offers convenient and professional service that makes the process easier than ever. With its long-standing reputation and customer-first…
Maycon Construction Services: Premier Roofing Solutions in Huntington
Image: https://www.globalnewslines.com/uploads/2025/01/1735918960.jpg
Huntington, NY - Maycon Construction Services is revolutionizing roofing services in Huntington with a commitment to quality, durability, and customer satisfaction. Specializing in Roof Repair Huntington [https://www.google.com/maps?cid=4993935758546148342], the company ensures homes and businesses are protected from leaks, weather damage, and structural issues.
The team at Maycon Construction Services employs state-of-the-art techniques and premium materials to deliver lasting results. Their Roof Replacement Huntington [https://www.google.com/maps/place/Maycon+Construction+Services/@38.4112395,-82.36617,17z/data=!3m1!4b1!4m6!3m5!1s0x8846079778fdc4b5:0x454e061d07439bf6!8m2!3d38.4112395!4d-82.36617!16s%2Fg%2F11sqq7wlm7?authuser=0&hl=en&entry=ttu&g_ep=EgoyMDI0MTIwOC4wIKXMDSoASAFQAw%3D%3D] services are designed to provide an upgrade…
SCHOOL OF ROCK HUNTINGTON READY TO ROCK N’ ROLL
Huntington, NY (November 17, 2016) – School of Rock, the leader in performance-based music education, announces the opening of its newest school in Huntington, New York, located at 145 East Main Street, Huntington, New York 11743. Opening on November 19, the school will host a party from 11 a.m. to 4 p.m., featuring live music from School of Rock students. In addition to the opening party, School of Rock Huntington…
Huntington Beach Real Estate Agent Launches Luxury Home Buying Experience
The Malakai Sparks Group, a Huntington Beach, California-based realty agency spearheaded by president and real estate expert Malakai Sparks, announced the launch of its Huntington Beach Home Buying Experience service, which encompasses “curated experiences” from the entire Malakai Sparks Group team. Designed for the purpose of allowing prospective buyers to take in all Huntington Beach has to offer prior to purchasing a home – while making sure the area is…
Gershow Recycling of Huntington Hosts Customer Appreciation Day
On August 24, Gershow Recycling hosted its Customer Appreciation Day at its Huntington Station facility. Those in attendance received giveaways, enjoyed food, games and the chance to win raffle prizes provided by Gershow and WBAB Radio (102.3 FM), which also provided music for the event.
Gershow has eight locations in Brooklyn, New Hyde Park, Valley Stream, Freeport, Lindenhurst, Huntington Station, Bay Shore and Medford. For more information, call (631) 289-6188…
